2nd Quarter - Report

PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE for PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$33,176
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2020 $33,176 Replaced
2nd Quarter - Amendment Sep 16, 2020 $33,176 Replaced
2nd Quarter - Amendment Sep 24, 2020 $33,176 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Eat for Health Act (no bill number yet). Healthy Future Students and Earth Act (to be introduced soon, no bill number yet) All provisions related to Nutrition Continuing Medical Education, school foods, federal nutrition policy. Retirement of NIH-owned Alamogordo chimpanzees to sanctuary Animal welfare oversight problems by NIH due to COVID-19 Requested Congress send a letter to NIH asking it to fund nonanimal COVID-19 research only and prioritize human-based research in NIH strategic planning and funding strategies. Requested Congress send a letter to FDA asking it to commit to ending agency and industry animal tests, starting with its COVID-19 response. Drafted bill language for a future COVID-19 funding package (unspecified) to end agency and industry animal tests, in addition to providing funding for NCATS (NIH) to advance human-based approaches and increased funding for NIMHD (NIH) to ensure diversity in preclinical research involving human subjects or biospecimens. Hosted a congressional briefing on why we need to prioritize human-based research in NIH and FDA funding strategies and strategic planning to confront COVID-19. Research priorities for the The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership

LobbyistCovered position, as disclosed
EMILY ANDERSON —
ELIZABETH BAKER —
CATHARINE ELIZABETH KREBS —
ANN LAM —
RYAN MERKLEY —
KRISTIE SULLIVAN —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.